The Manufacturers Life Insurance Company Trims Holdings in Elanco Animal Health Incorporated $ELAN

The Manufacturers Life Insurance Company lowered its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 14.2% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 6,229,045 shares of the company’s stock after selling 1,034,117 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Elanco Animal Health were worth $149,061,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. Maverick Capital Ltd. increased its stake in shares of Elanco Animal Health by 35.5% in the 1st quarter. Maverick Capital Ltd. now owns 144,457 shares of the company’s stock worth $3,457,000 after acquiring an additional 37,864 shares during the last quarter. Lazard Asset Management LLC boosted its position in shares of Elanco Animal Health by 25.1% during the 1st quarter. Lazard Asset Management LLC now owns 90,154 shares of the company’s stock valued at $2,157,000 after acquiring an additional 18,089 shares during the last quarter. Castleark Management LLC grew its holdings in shares of Elanco Animal Health by 931.4% in the first quarter. Castleark Management LLC now owns 355,950 shares of the company’s stock valued at $8,518,000 after purchasing an additional 321,440 shares during the period. Gabelli Funds LLC grew its holdings in shares of Elanco Animal Health by 1.6% in the first quarter. Gabelli Funds LLC now owns 134,250 shares of the company’s stock valued at $3,213,000 after purchasing an additional 2,150 shares during the period. Finally, Compound Planning Inc. increased its position in Elanco Animal Health by 7.4% during the first quarter. Compound Planning Inc. now owns 22,891 shares of the company’s stock worth $548,000 after purchasing an additional 1,579 shares during the last quarter. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Elanco Animal Health

In other news, CEO Jeffrey N. Simmons purchased 4,971 shares of the firm’s stock in a transaction on Friday, May 15th. The shares were bought at an average cost of $20.09 per share, for a total transaction of $99,867.39. Following the completion of the purchase, the chief executive officer directly owned 171,971 shares of the company’s stock, valued at approximately $3,454,897.39. This trade represents a 2.98% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Rajeev A. Modi purchased 4,911 shares of the stock in a transaction dated Friday, May 15th. The shares were purchased at an average price of $20.35 per share, with a total value of $99,938.85. Following the completion of the transaction, the insider owned 160,812 shares of the company’s stock, valued at approximately $3,272,524.20. This trade represents a 3.15% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Corporate insiders own 1.14% of the company’s stock.

Elanco Animal Health Stock Up 0.5%

Shares of NYSE:ELAN opened at $25.53 on Wednesday. The business has a 50-day moving average price of $24.24 and a 200 day moving average price of $24.01. The company has a current ratio of 2.16, a quick ratio of 1.12 and a debt-to-equity ratio of 0.60. The company has a market capitalization of $12.75 billion, a price-to-earnings ratio of -51.05, a PEG ratio of 1.66 and a beta of 1.68. Elanco Animal Health Incorporated has a 12-month low of $13.39 and a 12-month high of $27.72.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.06. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The firm had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.28 billion. During the same period in the previous year, the firm earned $0.37 EPS. Elanco Animal Health’s revenue was up 14.9% on a year-over-year basis. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. Sell-side analysts expect that Elanco Animal Health Incorporated will post 1.11 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have commented on ELAN. Piper Sandler reaffirmed an “overweight” rating on shares of Elanco Animal Health in a research note on Monday, June 29th. Wall Street Zen cut shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 24th. Citigroup raised their price target on shares of Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Weiss Ratings lowered shares of Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Finally, Morgan Stanley upped their price objective on Elanco Animal Health from $23.00 to $26.00 and gave the company an “equal weight” rating in a report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Elanco Animal Health has a consensus rating of “Moderate Buy” and a consensus price target of $28.73.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.